Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Breast 2Thoracic 1Dermatologic 1

Conditions

Glioblastoma 52Brain Neoplasms 28Glioma 22Gliosarcoma 19Melanoma 18Astrocytoma 17Central Nervous System Neoplasms 11Oligodendroglioma 10Neoplasms 9Neoplasm Metastasis 8Recurrence 6Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Lymphoma 4Ependymoma 4Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Sarcoma, Ewing 2Neurologic Manifestations 2Neuroectodermal Tumors, Primitive 2Neoplasms, Second Primary 2Meningeal Carcinomatosis 2Medulloblastoma 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Tetanus 1Spinal Cord Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Recurrent 1

Interventions

Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Second Primary × Temozolomide × Clear all
NCT00638963 2017-06-14

STOP

Merck Sharp & Dohme LLC

Phase 2 Terminated
6 enrolled 9 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms, Second Primary

NCT00629187 2012-04-27

CN-306

Tufts Medical Center

Phase 1 Terminated
2 enrolled
BreastCNSDermatologicThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Central Nervous System Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡